5 results
8-K
EX-99.1
NRIX
Nurix Therapeutics Inc
8 Jan 24
Regulation FD Disclosure
7:03am
volunteer study NX-5948 in Inflammation & Immunology
Oral daily dosing Phase 1a Accelerated titration / 3+3 escalation (n∼60a) CLL/SLL, MCL, DLBCL, FL
S-1
EX-10.10
NRIX
Nurix Therapeutics Inc
2 Jul 20
IPO registration
4:04pm
Clinical Trial), the administration of the first dose of a Licensed Product to the first patient (or volunteer, as relevant) participating … Product or placebo to the first patient (or volunteer, as relevant) participating in such Clinical Trial.
1.114 “Invention” means any process, method
S-1
EX-10.9
NRIX
Nurix Therapeutics Inc
2 Jul 20
IPO registration
4:04pm
of the first dose of a Licensed Product to the third patient (or volunteer, as relevant) participating in such Clinical Trial or (b) with respect to any … (or volunteer, as relevant) participating in such Clinical Trial.
1.108 “Interim Data Package” means, with respect to any Collaboration Target or Tabled
DRS
EX-10.10
NRIX
Nurix Therapeutics Inc
5 May 20
Draft registration statement
12:00am
Clinical Trial portion of a Phase 1/2 Clinical Trial), the administration of the first dose of a Licensed Product to the first patient (or volunteer … of the first dose of a Licensed Product or placebo to the first patient (or volunteer, as relevant) participating in such Clinical Trial.
1.114
DRS
EX-10.9
NRIX
Nurix Therapeutics Inc
5 May 20
Draft registration statement
12:00am
), the administration of the first dose of a Licensed Product to the third patient (or volunteer, as relevant) participating in such Clinical Trial or (b … to the first patient (or volunteer, as relevant) participating in such Clinical Trial.
1.108 “Interim Data Package” means, with respect to any
- Prev
- 1
- Next